![Author ORCID: We display the ORCID iD icon alongside authors names on our website to acknowledge that the ORCiD has been authenticated when entered by the user. To view the users ORCiD record click the icon. [opens in a new tab]](https://www.cambridge.org/engage/assets/public/coe/logo/orcid.png){kind=logo}
Abstract
Background: Severe mental disorders are associated with increased risk of metabolic dysfunction. The objective of this study was to compare metabolic profiles across three proposed pathophysiological subtypes of common mood disorders (“hyperarousal-anxious depression”, “circadian-bipolar”, and “neurodevelopmental-psychosis”).
Methods: 790 young people (aged 16 to 25; mean age 20.70 ± 4.91) were recruited from early intervention mental health services between 2004 and 2024 and assigned to three mood disorder subgroups (hyperarousal-anxious depression (n = 656), circadian-bipolar (n = 95), and neurodevelopmental-psychosis (n = 39)). We conducted cross-sectional assessments and between-group comparisons of metabolic and immune risk factors. Immune-metabolic markers included body mass index (BMI), fasting glucose (FG), fasting insulin (FI), Homeostasis Model Assessment-Insulin Resistance (HOMA2-IR), C-reactive protein (CRP), and blood lipids.
Results: There were significant between-group differences in FG (F = 3.159, p = 0.043), FI (F = 3.488, p = 0.031), and HOMA2-IR (F = 3.907, p = 0.020). Post-hoc comparisons showed fasting insulin and HOMA2-IR were significantly higher in the circadian-bipolar group as compared to hyperarousal-anxious depression (p = 0.049 and p = 0.028, respectively). We then differentiated those with the hyperarousal-anxious subtype on the on the basis of low versus high BMI (< 25kg/m2 vs. > 25kg/m2 respectively). The circadian-bipolar group had higher fasting glucose, fasting insulin, HOMA2-IR, and HDL cholesterol than those with low BMI.
Conclusions: Circadian disturbance may be driving increased rates of metabolic dysfunction among youth with emerging mood disorders, while increased BMI also remains a key determinant. Implications for assessment and early interventions are discussed.
Supplementary materials
Title
Supplementary Tables
Description
Table S1. Descriptive comparison of demographics and immune-metabolic markers between each illness pathway.
Table S2. Partial correlations between immune-metabolic markers controlled for age and gender (r(p)).
Table S3. Partial correlations between immune-metabolic markers controlled for age, gender and BMI (r(p)).
Table S4. Pos-hoc pairwise analysis of significant groups differences in demographic and metabolic variables (I-J) found in Table 1 based on estimated marginal means (Bonferroni adjusted).
Table S5. Descriptive comparison of demographics and immune-metabolic markers between each illness group and between individuals in the anxiety-depression group with low and high BMI.
Table S6. Post-hoc pairwise analysis of significant groups differences (I-J) found in Table 5 based on estimated marginal means (Bonferroni adjusted).
Actions